Skip to main content
Erschienen in: Pituitary 5/2017

06.06.2017

Acromegaly: surgical results in 548 patients

verfasst von: Cecilia Fernández Mateos, Maria García-Uria, Tomás Lucas Morante, José García-Uría

Erschienen in: Pituitary | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this study was to quantified the results of microsurgery, in all the patients with acromegaly treated by the same endocrinologist and the same surgeon between 1975 and 2015.

Methods

A series of 548 patients with acromegaly were operated and followed-up from 6 months to 40 years. Patients were selected according to five criteria: (1) Operated by the same surgeon. (2) No previous treatment. (3) Complete endocrinological preoperative studies including GH, OGTT, IGF-I, PRL test and TC/MRI. (4) Complete postoperative endocrinological evaluation for at least one determination of GH, OGTT, PRL test and IGF-I six months after surgery. (5) All the patients were supervised by the same endocrinologist.

Results

Microadenomas were present in 119 patients and 109 (91,5%) achieved remission. Non invasive macroadenomas were present in 200 patients and 164 achieved remission (82%). Results were worse for invasive macroadenomas but even with great invasions some patients achieved clinical remission. Follow-up range from 6 months to 40 years (mean 3.3 ± 2.3) A long term follow-up of 15 years was achieved in 61 patients. Four of them had a recurrence 4, 7, 8, 12 years after surgery (6.5%). There was not mortality and the rate of complications was low.

Conclusions

Surgery remains the first line of therapy for a majority of acromegalic patients. This series proves to be very valuable in circumscribed adenomas but also in invasive tumours. Levels of GH and IGF-I were decreased in almost all the patients without remission.
Literatur
2.
Zurück zum Zitat Wilson CB (1990) Role of surgery in the management of pituitary tumors. Neurosurg Clin N Am 1(1):139–159PubMed Wilson CB (1990) Role of surgery in the management of pituitary tumors. Neurosurg Clin N Am 1(1):139–159PubMed
3.
Zurück zum Zitat Fahlbusch R, Buchfelder J (2001) Surgical management of acromegaly. In: Wass J (ed) Handbook of acromegaly. BioScientifica, Bristol, pp 41–47 Fahlbusch R, Buchfelder J (2001) Surgical management of acromegaly. In: Wass J (ed) Handbook of acromegaly. BioScientifica, Bristol, pp 41–47
4.
Zurück zum Zitat García-Uria J, Del Pozo J, Bravo G et al (1978) Functional treatment of acromegaly by transphenoidal microsurgery. J Neurosurg 49:36–40CrossRefPubMed García-Uria J, Del Pozo J, Bravo G et al (1978) Functional treatment of acromegaly by transphenoidal microsurgery. J Neurosurg 49:36–40CrossRefPubMed
5.
Zurück zum Zitat García-Uría J, Lucas T, Bravo G. et al (1997) Acromegaly: long term results in 300 patients. J Endocrinol Invest 20(supl):98–100 García-Uría J, Lucas T, Bravo G. et al (1997) Acromegaly: long term results in 300 patients. J Endocrinol Invest 20(supl):98–100
6.
Zurück zum Zitat Laws ER (1979) Neurosurgical management of acromegaly. Results in 82 patients treated between 1972–1977. J Neurosurg 50(4):454–461CrossRefPubMed Laws ER (1979) Neurosurgical management of acromegaly. Results in 82 patients treated between 1972–1977. J Neurosurg 50(4):454–461CrossRefPubMed
7.
Zurück zum Zitat Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148CrossRefPubMed Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148CrossRefPubMed
8.
Zurück zum Zitat Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3935CrossRefPubMed Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3935CrossRefPubMed
9.
Zurück zum Zitat Melmed S, Casanueva F, Lamberts S, et al (2002) Guidelines form acromegaly management. J Clin Endocrinol Metab 87(9):4054–4058CrossRef Melmed S, Casanueva F, Lamberts S, et al (2002) Guidelines form acromegaly management. J Clin Endocrinol Metab 87(9):4054–4058CrossRef
12.
Zurück zum Zitat Hardy J (1969) Surgery of the pituitary gland using transsphenoidal approach. Ann Chir 21(15):1011–22 Hardy J (1969) Surgery of the pituitary gland using transsphenoidal approach. Ann Chir 21(15):1011–22
13.
Zurück zum Zitat Colao A, Attanasio R, Pivonello R et al (2006) Partial surgical removal of growth hormona-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85–92CrossRefPubMed Colao A, Attanasio R, Pivonello R et al (2006) Partial surgical removal of growth hormona-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85–92CrossRefPubMed
14.
Zurück zum Zitat Campbell PG, Kenning E, Andrews DW et al (2010) Outcomes after a purely endoscopic transphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E5CrossRefPubMed Campbell PG, Kenning E, Andrews DW et al (2010) Outcomes after a purely endoscopic transphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E5CrossRefPubMed
15.
Zurück zum Zitat Gondim JA, Almeida JP, Alburqueque LA et al (2010) Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus 95(7):3141–3148 Gondim JA, Almeida JP, Alburqueque LA et al (2010) Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus 95(7):3141–3148
16.
Zurück zum Zitat Hazer DB, Isik S, Berker M (2013) Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg 119(6):1467–1477CrossRefPubMed Hazer DB, Isik S, Berker M (2013) Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg 119(6):1467–1477CrossRefPubMed
17.
Zurück zum Zitat Hofstetter CP, Mannaa RH, Mubita L et al (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E6CrossRefPubMed Hofstetter CP, Mannaa RH, Mubita L et al (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E6CrossRefPubMed
18.
Zurück zum Zitat Wagenmakers MA (2011) Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormona-secreting adenomas. Acta Neurochir 153(7):1391–1399 Wagenmakers MA (2011) Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormona-secreting adenomas. Acta Neurochir 153(7):1391–1399
19.
Zurück zum Zitat Zada G, Cavallo L, Esposito F, et al (2010) Transsphenoidal Surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations. Neurosurg Focus 29(4):E8.10 Zada G, Cavallo L, Esposito F, et al (2010) Transsphenoidal Surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations. Neurosurg Focus 29(4):E8.10
Metadaten
Titel
Acromegaly: surgical results in 548 patients
verfasst von
Cecilia Fernández Mateos
Maria García-Uria
Tomás Lucas Morante
José García-Uría
Publikationsdatum
06.06.2017
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 5/2017
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-017-0813-y

Weitere Artikel der Ausgabe 5/2017

Pituitary 5/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.